en-clofert 50 (Androxal), in development by Repros Therapeutics Inc, is a non-steroidal estrogen receptor antagonist that promotes gonadotropin-dependent testosterone secretion by the testes.Enclomiphene 50 constitutes the trans- stereoisomer of clomiphene citrate, a drug that has been widely prescribed for
several decades for the treatment of female ovulatory dysfunction.

In clinical trials conducted to date, enclomiphene 50 demonstrated significant efficacy in the physiological restoration of testosterone levels in males with secondary hypogonadism. The compound also exhibited an unanticipated favorable effect on fasting plasma glucose; this result has been accompanied by rapidly
accumulating evidence from other researchers for a bidirectional relationship between low serum testosterone and obesity/metabolic syndrome (syndrome X) in men.

Artesunate 50 is a water-soluble hemisuccinate derivative of artemisinin. It is unpredictable in neutral remedy as well as the injectable formulation must be prepared right away prior to use in 5% (w/v) sodium bicarbonate option to produce the salt sodium artesunate. After parenteral management, it is swiftly hydrolyzed
to the energetic metabolite dihydroartemisinin. The dental formulation is possibly hydrolyzed completely prior to getting in the systemic blood circulation.